uniQure (NASDAQ:QURE) Stock Price Down 3.7% – Time to Sell?

Shares of uniQure N.V. (NASDAQ:QURE) dropped 3.7% during trading on Tuesday . The stock traded as low as $16.85 and last traded at $17.2650. Approximately 173,813 shares changed hands during trading, a decline of 94% from the average daily volume of 3,093,979 shares. The stock had previously closed at $17.92.

Wall Street Analysts Forecast Growth

QURE has been the topic of several recent analyst reports. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $9.00 price target (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Stifel Nicolaus set a $14.00 price target on shares of uniQure in a report on Monday, March 2nd. Finally, Barclays dropped their price target on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $42.75.

uniQure Stock Performance

The business’s fifty day moving average price is $17.99 and its 200-day moving average price is $28.87. The company has a debt-to-equity ratio of 0.25, a quick ratio of 10.43 and a current ratio of 10.43. The stock has a market cap of $1.08 billion, a PE ratio of -5.00 and a beta of 0.75.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. The firm had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. As a group, equities research analysts forecast that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Christian Klemt sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $108,720.00. Following the transaction, the chief financial officer owned 226,581 shares of the company’s stock, valued at approximately $2,052,823.86. This trade represents a 5.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jeannette Potts sold 3,412 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $30,912.72. Following the completion of the transaction, the insider directly owned 138,483 shares in the company, valued at approximately $1,254,655.98. The trade was a 2.40% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 49,396 shares of company stock valued at $722,734. 4.79% of the stock is owned by insiders.

Hedge Funds Weigh In On uniQure

A number of institutional investors and hedge funds have recently made changes to their positions in QURE. Woodline Partners LP boosted its holdings in shares of uniQure by 25.0% in the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after buying an additional 35,175 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of uniQure in the second quarter worth approximately $497,000. Marshall Wace LLP boosted its holdings in shares of uniQure by 276.5% in the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after buying an additional 163,749 shares during the last quarter. California State Teachers Retirement System purchased a new position in shares of uniQure in the second quarter worth approximately $540,000. Finally, Ameriprise Financial Inc. boosted its holdings in shares of uniQure by 38.6% in the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after buying an additional 212,218 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.